Gamida Cell Ltd

NASDAQ:GMDA   3:59:54 PM EDT
3.99
-0.11 (-2.68%)
Products, Regulatory

Gamida Cell Provides Pipeline Update, Including Detailed Results Of Pivotal Phase 3 Clinical Study Of Omidubicel, And Prepares To Start BLA Submission By End Of 2020

Published: 12/09/2020 12:06 GMT
Gamida Cell Ltd (GMDA) - Gamida Cell Provides Pipeline Update, Including Detailed Results of Pivotal Phase 3 Clinical Study of Omidubicel, and Prepares to Start Bla Submission by End of 2020.
Gamida Cell Ltd - Preparing to Be Launch Ready in Anticipation of Potential FDA Approval As Early As Q4 of 2021 for Omidubicel.
Gamida Cell Ltd - Anticipates Reporting Full Data Set in a Peer-reviewed Setting in First Half of 2021 for Omidubicel.